Metabocure

Company Overview

Snapshot

Founded in July 2024 by Ronen Sarusi, MetaboCure operates with 1–10 employees. The company secured a grant in December 2024 from the Israel Innovation Authority, marking a significant early milestone in its development.

Business overview

MetaboCure is a biopharmaceutical company focused on developing novel therapies for cancer cachexia and other metabolic complications. The company's core technology centers on Nuforal, an HNF4α mRNA/LNP-based drug designed to restore HNF4α levels in the liver, thereby reversing symptoms of cachexia, reducing weight loss, and improving survival rates in cancer models. MetaboCure operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.

Strategic signal

In January 2025, MetaboCure's mission to restore life to cancer cachexia patients was highlighted, emphasizing the company's focus on addressing a critical unmet medical need. This signals a strong commitment to advancing its Nuforal drug candidate and underscores the potential for significant impact in oncology and metabolic health, positioning the company for future strategic partnerships and investment in the biopharmaceutical space.

Company Intelligence Q&A

What is MetaboCure's primary focus?

MetaboCure is a biopharmaceutical company dedicated to developing novel therapies for cancer cachexia and other metabolic complications, aiming to restore patients’ strength and improve clinical outcomes.

What is Nuforal?

Nuforal is MetaboCure's HNF4α mRNA/LNP-based drug candidate for the treatment of cancer cachexia. It works by restoring HNF4α levels in the liver to reverse disease symptoms.

When was MetaboCure founded?

MetaboCure was founded in July 2024.

Which organization provided a grant to MetaboCure?

In December 2024, MetaboCure secured a grant from the Israel Innovation Authority.

What is the strategic importance of HNF4α in MetaboCure's research?

MetaboCure's research indicates that the transcription factor HNF4α, crucial for regulating liver metabolism, is suppressed during cachexia. Restoring its levels is key to reversing symptoms like weight loss and tumor growth.